1. Anti‐BDCA2 monoclonal antibody inhibits plasmacytoid dendritic cell activation through Fc‐dependent and Fc‐independent mechanisms. Issue 4 (11th March 2015) Authors: Pellerin, Alex; Otero, Karel; Czerkowicz, Julie M; Kerns, Hannah M; Shapiro, Renée I; Ranger, Ann M; Otipoby, Kevin L; Taylor, Frederick R; Cameron, Thomas O; Viney, Joanne L; Rabah, Dania Journal: EMBO molecular medicine Issue: Volume 7:Issue 4(2015:Apr.) Page Start: 464 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles. Issue 11 (5th August 2017) Authors: Chamberlain, Chris; Colman, Peter J; Ranger, Ann M; Burkly, Linda C; Johnston, Geoffrey I; Otoul, Christian; Stach, Christian; Zamacona, Miren; Dörner, Thomas; Urowitz, Murray; Hiepe, Falk Journal: Annals of the rheumatic diseases Issue: Volume 76:Issue 11(2017) Page Start: 1837 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗